Administrative Core

行政核心

• 批准号: 10261953
• 负责人: Monica Kraft
• 金额: $ 14.68万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10261953
• 关键词: 2019-nCoV; Adherence; Advisory Committees; Allergic Disease; Anions; Arizona; Asthma; Attenuated; Biological; Biological Response Modifiers; Collaborations; Collection; Communication; Communities; Data; Data Analyses; Ensure; Ethics; Fostering; Funding Opportunities; Future; Grant; Guidelines; Health; Human Resources; Immune; Immune response; Immunologic Factors; Immunomodulators; Infection; Inflammation; Inflammatory Response; Influenza A virus; Information Dissemination; Infrastructure; Institution; Lipids; Mediator of activation protein; Medical center; Molecular; Monitor; Natural Immunity; Participant; Performance; Phosphatidylglycerols; Phosphatidylinositols; Program Reviews; Publications; Pulmonary Surfactant-Associated Protein A; Recording of previous events; Regulation; Research; Research Activity; Research Personnel; Resources; Role; Sampling; Schedule; Shipping; TOLLIP gene; Time; Translating; Travel; United States National Institutes of Health; Universities; Vertebrates; Viral; Virus Diseases; Vision; Work; asthma exacerbation; base; clinical practice; conflict resolution; cost; data management; follower of religion Jewish; human subject; innate immune mechanisms; meetings; member; novel therapeutics; operation; programs; success; surfactant; symposium; synergism

This U19 Asthma and Allergic Diseases Cooperative Research Center (AACDRC) Program brings together a team of investigators in three interactive projects and two cores to focus on the pathobiology of specific innate immune mechanisms in viral infection and asthma. In the renewal of our AADCRC program, we will continue to focus on the critical and often understudied innate immune factors surfactant protein-A (SP-A), the anion lipids of surfactant, (palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI)) and Toll interacting protein (Tollip), an innate immune mediator known to cross talk with SP-A and the anionic lipids. Each of these mediators works synergistically to modulate inflammatory and immunologic responses in asthma and infection given their complementary functions. Our exciting preliminary data underpin our program’s overall hypothesis that POPG/PI, Tollip and SP-A function as unique immune modulators that attenuate the impact of specific viral infections (RV-C, Influenza A and SARS-CoV-2) in type-2 asthma. The investigators in this program have a long history of collaboration at the. University of Arizona and National Jewish Health; Cedar Sinai Medical Center is now included in this renewal. The Administrative Core (Core A) of this Program will perform an important role to maintain productive and vibrant collaboration, ensure and track adherence to NIH and other relevant regulations and guidelines, and manage activities that will continue to strengthen the research community surrounding this Program. The Administrative Core has the following Specific Aims: (1) Manage the day-to-day administrative details and programmatic needs of the AADCRC program by providing fiscal management, administering subcontracts, assuring that regulatory requirements in are met, and monitoring of progress with program objectives; (2) Create an infrastructure to facilitate communication between the projects, cores and. investigators, and NIH Program Directors and to provide conflict resolution should it be necessary; (3) Assist with dissemination of research findings in a timely fashion to the scientific community, both locally and nationally, and provide information to the public, including study participants; 4) Implement the Infrastructure and Opportunity Fund for the AADCRC. Our proposal builds upon our active and productive collaborations of over 20 years and will significantly enhance our understanding of the innate molecular mechanisms underlying the interaction between type 2 inflammation in and viral exacerbations of asthma. The strong synergy among our projects will accelerate progress toward novel therapies by demonstrating that the innate immune components under study protect against viral infection in asthma.

U19 哮喘和过敏性疾病合作研究中心 (AACDRC) 项目汇集了 三个互动项目和两个核心的研究团队专注于特定先天的病理学 病毒感染和哮喘中的免疫机制 在更新我们的 AADCRC 计划时，我们将继续。 重点关注关键且经常未被充分研究的先天免疫因子表面活性剂蛋白-A (SP-A)， 表面活性剂的阴离子脂质（棕榈酰油酰磷脂酰甘油 (POPG) 和磷脂酰肌醇 (PI)） Toll 相互作用蛋白 (Tollip)，一种先天免疫介质，已知可与 SP-A 和 这些介质中的每一种都协同作用来调节炎症和免疫。 鉴于它们的互补功能，我们令人兴奋的初步数据支持了哮喘和感染的反应。 我们项目的总体假设是 POPG/PI、Tollip 和 SP-A 作为独特的免疫调节剂 减轻 2 型特定病毒感染（RV-C、甲型流感和 SARS-CoV-2）的影响 该项目的研究人员与亚利桑那大学有着悠久的合作历史。 国家犹太健康中心；雪松西奈医疗中心现已包含在此次更新中。 该计划的（核心 A）将在保持富有成效和充满活力的合作方面发挥重要作用，确保 跟踪对 NIH 和其他相关法规和指南的遵守情况，并管理将 继续加强围绕该计划的研究社区 行政核心拥有： 具体目标如下： (1) 管理日常行政细节和计划需求 AADCRC 计划通过提供财务管理、管理分包合同、确保监管 (2) 打造基础设施 促进项目、核心研究人员和 NIH 项目主管之间的沟通。 （三）协助及时传播研究成果 向当地和国家科学界传播时尚，并向公众提供信息，包括 研究参与者；4) 实施我们的提案建立的基础设施和机会基金。 经过 20 多年的积极和富有成效的合作，这将大大增强我们的理解 2 型炎症和病毒之间相互作用的先天分子机制 我们的项目之间的强大协同作用将加速新药研发的进展。 通过证明所研究的先天免疫成分可以预防病毒来治疗 哮喘感染。